Shares of Curis, Inc. (NASDAQ:CRIS) have earned a consensus recommendation of “Hold” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $6.50.
A number of research firms recently commented on CRIS. Zacks Investment Research raised shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Thursday. Guggenheim began coverage on shares of Curis in a research report on Monday, October 23rd. They set a “buy” rating and a $7.00 target price for the company.
In other news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $1.06 per share, with a total value of $53,000.00. Following the completion of the transaction, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at approximately $122,843.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.07% of the company’s stock.
Curis (CRIS) traded down $0.03 during trading hours on Friday, reaching $0.55. 970,303 shares of the company were exchanged, compared to its average volume of 1,560,000. Curis has a 12 month low of $0.54 and a 12 month high of $3.22. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15. The stock has a market capitalization of $90.30, a PE ratio of -1.41 and a beta of 1.56.
ILLEGAL ACTIVITY WARNING: “Analysts Set Curis, Inc. (CRIS) Price Target at $6.50” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/02/08/analysts-set-curis-inc-cris-price-target-at-6-50.html.
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.